Merck gives up on developing Aranesp copycat

Merck's (NYSE: MRK) decision to end efforts to copy Amgen's blockbuster Aranesp anemia drug shows how the emerging field of developing generic versions of biotechnology therapies won't be easy to enter. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.